ReviewBiomaterials research2025
Nanomaterials for Combating Cancer while Safeguarding Organs: Safe and Effective Integrative Tumor Therapy.
Review in Biomaterials research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a leading cause of mortality globally. Combating cancer while safeguarding organs (CCSO) has emerged as a specialized field that employs a multifaceted approach to cancer management. Postsurgery solid tumors face issues such as recurrence and organ dysfunction due to residual cancer, resection, inflammation, and infections. Adjuvant and preventive treatments may also impair organ function, adding to treatment challenges. This review delineates the multifaceted landscape of multidimensional nanomaterials, spanning from 0-dimensional nanoparticles to 3-dimensional scaffolds, and their collaborative roles in concurrent cancer management and organ protection. We underscore the importance of nanomaterial synthesis, functionalization, and responsive release mechanisms in the tumor and organ microenvironments. A comprehensive analysis of nanomaterial applications in integrated cancer management, including melanoma, osteosarcoma, breast cancer, liver cancer, pancreatic cancer, and gastric cancer, is presented, highlighting their potential to overcome therapeutic challenges. The discourse also addresses the obstacles and future directions for nanomaterials for CCSO, offering valuable insights for advancing cancer management and organ protection. This review aims to enhance the comprehension and progress of nanomaterials for CCSO, fostering the development of more effective cancer management modalities.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.